This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As patients continue to morph into health consumers, facing rising out-of-pocket costs for deductibles and coinsurance shares, people are healthcare payers alongside their employers and government sponsors for insurance. For context, check out the third chart I’m sharing here from a recent survey into U.S.
Digital health technology has seen an incredible growth in the last few years, fueled by a combination of consumerization of wearable technologies, ubiquity of mobile devices, proliferation of technology incubators, attention by government health and regulatory agencies and involvement of large companies heretofore not focused on healthcare.
Andrew Barnhill, Head of Public Policy, Global Legal, IQVIA Alexandra Weiss, Director of Strategic Partnerships, PatientAdvocacy Organizations, IQVIA Diversity is paramount to the success of clinical research, both ethically and scientifically.
Other key trends to expect leading to 2023 will be: The rise of patientadvocacy roles in pharma companies. The increased use of real-world evidence (RWE) and patient involvement in clinical trials. The first FDA cleared DTx was reSET from Pear Therapeutics, cleared in November 2018. using consumer-generated technology.
Food and Drug Administration (FDA) as breakthrough devices. [1] 5] However, devices in earlier stages of the FDA approval process often lack the clinical evidence needed to satisfy the “reasonable and necessary” criteria to justify CMS’s establishment of a national coverage standard.
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content